A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies.
Fiche publication
Date publication
septembre 2015
Journal
Oncoimmunology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BENSUSSAN Armand
Tous les auteurs :
Sicard H, Bonnafous C, Morel A, Bagot M, Bensussan A, Marie-Cardine A
Lien Pubmed
Résumé
Cutaneous T-cell lymphomas (CTCLs) represent a group of rarely occurring and clinically and pathologically heterogeneous diseases that are considered incurable at advanced stages. Current treatments provide limited clinical benefit and are thus largely amenable to improvement. An antibody-based CTCL-specific immunotherapy targeting the KIR3DL2 receptor expressed by the tumor cells in CTCL is currently under development and has shown encouraging results in pre-clinical studies.
Mots clés
Antibody, CTCL, KIR3DL2, immunotherapy, non-clinical studies
Référence
Oncoimmunology. 2015 09;4(9):e1022306